Semiallogeneic cell hybrids and related methods for treating cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 16, 2000
Grant Date -
N/A
app pub date -
Sep 10, 1996
filing date -
Sep 10, 1996
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
An isolated cell having the characteristics of the cell line designated FO-1 #12 is provided. The cell FO-1 #12 is characterized as being .beta..sub.2 -microglobulin-deficient, neomycin-resistant and HAT-sensitive. A cell hybrid formed by the fusion of an FO-1 #12 cell or other cell described herein and a mammalian cell is provided. The patient-derived cell can be a tumor cell or other cell, such as a white blood cell. The patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, or others. A method of treating AIDS in a patient, comprising administering to the patient a cell hybrid provided herein, wherein the patient-derived white blood cell is derived from the patient being treated, is provided. A method of treating solid tumor in a patient, comprising administering to the patient a cell hybrid as provided herein, wherein the patient-derived tumor cell is derived from the patient being treated, is provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully